View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 6, 2022

China’s NMPA accepts Innovent and IASO Bio’s multiple myeloma therapy NDA

The acceptance of NDA is based on data obtained from an open-label, multi-centre, single-arm Phase I/II study.

The China National Medical Products Administration (NMPA) has accepted the new drug application (NDA) for Innovent and IASO Biotherapeutics’ Equecabtagene Autoleucel to treat relapsed and/or refractory multiple myeloma (R/R MM).

Equecabtagene Autoleucel is a fully human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy.

It is said to be the first BCMA-targeting CAR T-cell therapy in China.

The NDA acceptance is based on data obtained from an open-label, multi-centre, single-arm Phase I/II study, which is being conducted in the country.

According to the findings, Equecabtagene Autoleucel has less immunogenicity given a fully human scFv, robust expansion and prolonged persistence in vivo.

Innovent president Dr Yongjun Liu said: “We are glad about the NDA acceptance of Equecabtagene Autoleucel, a product candidate co-developed by Innovent and IASO Bio, and it will potentially to be the domestic first approved and launch-to-market BMCA CAR-T therapy for multiple myeloma.

“In the clinical studies, Equecabtagene Autoleucel demonstrated impressive efficacy and favorable safety profiles.

“We hope that this breakthrough therapy could be approved in the near future, and we will actively coordinate with all parties including the government authorities, hospitals, commercial insurance and charity funds to bring benefit to more multiple myeloma patients.”

IASO Bio and Innovent jointly granted the non-exclusive commercial rights of the fully-human BCMA CAR construct, which is used in Equecabtagene Autoleucel, to Sana Biotechnology in January this year.

In February this year, the US Food and Drug Administration’s (FDA’s) Office of Orphan Products Development (OOPD) granted Orphan Drug Designation (ODD) to Equecabtagene Autoleucel.

The NMPA has also accepted IND application of Equecabtagene Autoleucel for the expanded indication of Neuromyelitis Optica Spectrum Disorder (NMOSD).

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology